Novotech CEO to speak on Clinical Projects – Faster and Smarter it’s All in the Planning at the 46th DIA Annual Meeting June 13-17 in Washington, DC
June 15, 2010
Washington, DC, June 13, 2010 – Leading Australian contract clinical research company Novotech announced today that Novotech CEO Alek Safarian will be sharing the company’s Asia Region expertise and experience at DIA 2010 to be held in Washington, DC.
Safarian will speak on “Global Study Experiences: Lessons from Observing Regional Variations” which is part of the “Clinical Projects: Faster and Smarter? It’s All in the Planning! session.
Date: June 15, 2:00PM – 3:30PM
Session #: 246
Room #: 140B
Novotech is the largest full-service Australian CRO with an extensive operations footprint across Asia, and has helped global customers conduct trials across a population base of more than 1.5 billion people in the Australasian region.
Headquartered in Sydney, Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of Phase III trials.
“Judging by the growth in number of new clinical trials starting in the region over the last few years, Asia provides a tremendous untapped opportunity to the drug development industry,” said Safarian.
The DIA Annual Meeting is the premier event for professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products. There is no other industry meeting of its kind that can rival the breadth and depth of experience that this meeting delivers. With 25 content- area tracks, 330 sessions and 20 tutorials, presentations are geared to attendees at all disciplines, works settings, and experience levels.
Headquartered in Sydney with a regional hub in Malaysia, Novotech is focused on the Asia Pacific region with operations in nine countries including India and South Korea. Novotech also has worldwide reach through the company’s network of strategic partners. Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. As the largest independent CRO based in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region. Since 2006, Novotech has been recognized as Australia’s leading CRO by Frost & Sullivan in its Asia Pacific Excellence in Healthcare awards. For more information, please visit www.novotech-cro.com.
ABOUT THE DRUG INFORMATION ASSOCIATION (DIA)
DIA is a neutral, global, professional, member-driven association of nearly 18,000 industry, academia, and regulatory professionals involved in the discovery, development, and life cycle management of pharmaceuticals, medical devices, and related products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.
Australian office: +61 2 9006 1614
USA office: +1650 7985238